August biopharma layoffs impact just over 500, down 90% year over year. September 10, 2026 | Last month, biotech and pharma companies making or planning workforce cuts included three whose reductions will more than halve their workforces. Blueprint Medicines' layoffs will affect the most employees. The biopharma layoff picture improved year over year in August, based on BioSpace tallies. The number of biotech and pharma companies cutting or projecting they'll cut their workforces fell 48% to 12, while affected employees plunged 90% to 526. The sharp year-over-year decrease in impacted staff is because in August 2025, CSL announced it was cutting 15% of its workforce, a move estimated to affect around 4,350 employees. The Australian multinational's layoffs were part of a restructuring meant to streamline operations and boost clinical and commercial performance. Without that workforce reduction, the number of people affected by job cuts in August 2025 would have been 991, a figure that still easily tops the 526 impacted last month. In August 2026, the largest round of layoffs by staff count came at Blueprint Medicines, a subsidiary of France-based Sanofi. About a year after completing its $9.5 billion acquisition of Blueprint, Sanofi disclosed in a Worker Adjustment and Retraining Notification (WARN) notice that Blueprint is letting go of 229 employees at its Cambridge, Massachusetts, headquarters. The cuts will be effective Oct. 9, 2026, to June 25, 2027. Encouraging year-over-year layoff data for 2026 is not confined to August alone. The number of biopharmas making or projecting cuts has fallen every month, and total affected employees has dropped six times. It's worth noting, however, that not all layoff data in August was positive. There were month-over-month increases. The number of biopharmas trimming staff rose from six to 12 and affected employees from 466 to 526. And, while the increase in impacted staff was small, at 60 people, the scope of Pfizer's layoffs could be significant. Pfizer announced last month that it's adding $2.5 billion in cuts to an ongoing restructuring. The savings will mostly happen between 2027 and 2029, largely through technology and simplification efforts across the New York pharma's commercial, research and development (R&D) and manufacturing functions. Pfizer will incur a one-time cost of $2 billion for digital enablement, implementation and severance. The company has not specified how many jobs it will cut. The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major products like the blood thinner Eliquis. August 4, 2026 Arsenal, aTyr, Lisata will put large dents into workforces. Of the 12 biopharmas that announced or disclosed layoffs in August, three are letting go of over half of their workforces: Arsenal Biosciences, aTyr Pharma and Lisata Therapeutics. ArsenalBio is laying off 99 employees - "the majority of the company" - across its South San Francisco headquarters and Hayward, California, locations, a company spokesperson confirmed to BioSpace. The cuts may affect around 78% of the workforce, given the biotech had 127 employees a year ago after downsizing by 50%. Most of the latest layoffs will affect ArsenalBio's HQ, where 58 employees are being let go effective Oct. 29, according to a WARN notice. The cuts are tied to the company's significant strategic shift to focus efforts on development of in vivo CAR T therapies. aTyr is laying off about 60% of its workforce. The company announced the news last month, and a related SEC filing noted that the San Diego-based biotech will have around 20 employees left. aTyr is making the move to help focus resources on advancing its lead asset, efzofitimod, in interstitial lung disease (ILD), which causes inflammation and scarring in the lungs. The biotech's workforce changes include two executive departures. Chief Financial Officer Jill Broadfoot and General Counsel Nancy Denyes will step down Sept. 30 and transition to consultant roles. Brandon Yaras, vice president of finance, will become CFO Oct. 1. Lisata has cut about 72% of its full-time workforce, the Basking Ridge, New Jersey-based biotech announced last month. Given the company had 21 full-time staffers as of Dec. 31, 2025, the layoffs may have affected around 15 employees. Lisata attributed the workforce reduction to its need to reduce operating expenses and preserve cash to pursue strategic alternatives following a failed planned merger with Kuva Labs. The biotech has filed a lawsuit against Houston-based Kuva, alleging that the company breached the merger agreement. Like aTyr, Lisata's layoffs affected the C-suite. Kristen Buck, executive vice president of research and development and chief medical officer, was let go Aug. 3. 5 companies' cuts weren't their first in the past year. For ArsenalBio, Blueprint Medicines, Ensoma, Indivior Pharmaceuticals and Pfizer, their layoffs announced or disclosed in August were not their first workforce reductions in the preceding 12 months. * ArsenalBio cut 50% of its employees in September 2025, leaving the business with 127 people. The company was restructuring to extend its cash runway and position itself for its next phase of development, a spokesperson told Fierce Biotech. Added to the latest round of layoffs involving 99 employees, Arsenal's two rounds of cuts will affect about 226 people. * In November 2025, a few months after being acquired by Sanofi, a Sanofi spokesperson confirmed to BioSpace that an undisclosed number of Blueprint staffers would lose their jobs as part of a realignment initiative. Sanofi was prioritizing programs that aligned with its R&D strategy and offered the greatest patient value, according to the spokesperson. Blueprint's latest round of layoffs will affect 229 people. * Ensoma cut 50% of its staff, or 37 employees, in November 2025 to prioritize resources in the areas best poised to advance the Boston-based biotech's mission, CEO Jim Burns announced in a LinkedIn post at the time. The number of people the company's latest layoffs will affect is unknown. * In August 2025, Indivior announced it was cutting an undisclosed number of employees as part of a sweeping multiyear initiative to maximize the potential of its North Chesterfield, Virginia-based business. The number of people the company's latest layoffs will affect is also unknown. Those cuts are expected as part of a merger with Rockville, Maryland-based Supernus Pharmaceuticals. * Pfizer disclosed in an August 2025 WARN notice that it was laying off 100 employees at its Bothell, Washington, site starting that month. The company told Fierce Pharma the move was part of a push to improve research and development productivity and efficiency, with a sharpened focus on opportunities. In December 2025, Bloomberg reported Pfizer was letting go of more than 200 employees across Switzerland as part of a continuing effort to slow its cash burn. Added together, those workforce reductions affected 300 people. The scope of the pharma's latest round of layoffs is unknown. This month, the first three companies reported to be letting go of employees - Merck, Novartis and TScan Therapeutics - have all had prior workforce cuts within the past year. Layoff numbers exclude contract development and manufacturing organizations, contract research organizations, tools and services businesses and medical device firms. To tally the cuts, BioSpace compiles data for known workforce reductions. The number of employees affected is identified or estimated through confirmation from company officials as well as information in company press releases, Worker Adjustment and Retraining Notification (WARN) Act notices, SEC filings and other media outlets' reports. Not all companies disclose downsizing, and some share only the percentage of staff affected. Some biopharmas provide total numbers retrospectively rather than disclosing individual workforce reductions as they happen. Job market trends, layoffs and career advice to manage your life sciences career Angela Gabriel is content manager, life sciences careers, at BioSpace. She covers the biopharma job market, job trends and career advice, and produces client content. You can reach her at [email protected] and follow her on LinkedIn.

Sanofi to lay off 229 Blueprint employees, close offices. Sanofi is laying off 229 former Blueprint Medicines employees in Cambridge, MA and closing two legacy Blueprint facilities. The news comes just over a year after Sanofi's $9 billion acquisition of Blueprint, one of the biggest deals of 2025. Boston Business Journal broke the news, which pharmaphorum has independently verified with the company. "As part of the integration following our acquisition of Blueprint Medicines in July 2025, we made thoughtful organisational decisions to align our structure with our long-term business priorities and the needs of our commercial portfolio and pipeline," Sanofi said in an emailed statement. "These decisions were made carefully to position the organisation for future success while continuing to deliver for patients. Many Blueprint employees are joining Sanofi. Those affected by these decisions have already been informed and we will continue to provide multiple avenues of support through their transitions." Blueprint's facilities at 45 Sidney St and 38 Sidney St in Cambridge are closing, with remaining Blueprint employees reporting to Sanofi's East Cambridge office. Since the acquisition was finalised in July 2025, there's already been an exodus of Blueprint talent at the top levels of the company. All 13 members of Blueprint's leadership team (as listed on their website at the time) have left the company in the last year, with most departing in October of last year, according to LinkedIn. Chief scientific officer Percy Carter has been leading preclinical and translational sciences at Pfizer, chief commercial officer Philina Lee is now CEO at AdvanceCell, R&D president Fouad Namouni is CEO at Synolo Therapeutics, and three separate members of the team - chief medical officer Dr Becker Hewes, chief business officer Sherwin Sattarzadeh, and SVP corporate affairs Jim Baker - have landed in similar roles at Damora Therapeutics, a Boston biotech focused on blood disorders. Sanofi acquired Blueprint to secure the rights to Ayvakit/Ayvakyt (avapritinib), a tyrosine kinase inhibitor (TKI) that targets the KIT D816V mutation in ASM, an umbrella term that covers multiple disorders, including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell leukaemia (MCL). Ayvakit is the only approved medicine for ASM, which causes symptoms like itching, fever, abdominal pain, and nausea, and can also lead to organ damage, bone fractures, and anaemia. People with ASM typically have a life expectancy ranging from six months to around three-and-a-half years. According to recent Sanofi financial reports, Aykavit earned the company €367 million in net sales in the first half of 2026. 17 August, 2026